ABS course Map
-
menu_book
Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer
This prospective randomised trial assigned postmenopausal women with HR-positive breast cancer who had received 5 years of adjuvant endocrine therapy (n=3484) to receive either additional 2 or 5 years...
Michael Gnant et al | The New England Journal of Medicine
28.07.2021 | Added: 28.07.2021
Classifications: Adjuvant & Neoadjuvant Treatment
Keywords: Endocrine Therapy
menu_bookPublication menu_book -
desktop_windows
Colin McIlmunn | ABS Conference 2018
18.06.2018 | Added: 18.06.2018
Classifications: Breast Cancer Treatment
Keywords: Contralateral breast cancer
desktop_windowsWebcast desktop_windows -
desktop_windows
Dr XT Tan | ABS Conference 2017
15.05.2017 | Added: 15.05.2017
Classifications: Breast Cancer Treatment
Keywords: Contralateral breast cancer
desktop_windowsWebcast desktop_windows